Summary

KEY FINDINGS
The global surgical site infection control market is expected to record a CAGR of 4.50% during the forecast period, 2024-2032. The base year considered for the study is 2023, and the estimated period is between 2024 and 2032. The market study has also analyzed the impact of COVID-19 on the surgical site infection control market qualitatively as well as quantitatively.
Surgical site infection control refers to the comprehensive measures and protocols implemented before, during, and after surgical procedures to minimize the risk of infections at the incision site. It involves meticulous adherence to sterile techniques, proper preoperative skin preparation, effective antimicrobial prophylaxis, meticulous wound closure, and postoperative surveillance. These strategies aim to reduce the incidence of infections, promote patient safety, and enhance surgical outcomes.
MARKET INSIGHTS
Key enablers of the global surgical site infection control market growth:
• Surge in geriatric population
o The global landscape of healthcare is undergoing a significant transformation driven by demographic shifts, particularly the rapid increase in the geriatric population. As per the World Health Organization (WHO), by 2030, approximately one-sixth of the world’s population is projected to be aged 60 years or older, rising from 1 billion in 2020 to 1.4 billion.
o By 2050, this demographic is expected to double, reaching 2.1 billion individuals. This shift is profoundly impacting various facets of healthcare, including the prevalence of surgical procedures and associated risks such as surgical site infections (SSIs).
o The vulnerability of the elderly population to infections is exacerbated by weakened immune systems and underlying health conditions. This underscores the critical importance of robust surgical site infection control measures to mitigate infection risks among older patients.
o Healthcare providers are increasingly focusing on advanced technologies and protocols tailored to address the specific challenges posed by aging populations. As the geriatric demographic continues to expand globally, the demand for effective infection prevention and control in surgical environments is set to rise.
• Increased incidence of hospital-acquired infections
• Implementation of regulatory guidelines for the prevention of hospital-acquired infections
Key growth restraining factors of the global surgical site infection control market:
• Lack of awareness with regard to hospital-acquired infections
o Despite the significant impact of hospital-acquired infections (HAIs) on patient outcomes and healthcare costs, there remains a lack of awareness among both healthcare providers and patients regarding the risks and consequences of HAIs, including surgical site infections (SSIs).
o This lack of awareness may lead to inadequate implementation of infection prevention measures, delayed diagnosis and treatment of SSIs, and overall suboptimal management of infection control protocols, thereby posing a challenge for the surgical site infection control market in effectively addressing and mitigating the risk of SSIs.
• Surging medical waste due to the use of medical disposable items
• Rising use of outpatient treatments
Surgical Site Infection Control Market | Top Trends
o The rising rate of surgical procedures is driving the demand for innovative solutions in the surgical site infection control market, as the increased volume of surgeries heightens the importance of infection prevention measures.
o Minimally invasive surgeries (MIS) and outpatient procedures are expanding due to their benefits, such as reduced recovery times, lower costs, and decreased risk of complications. This shift towards less invasive techniques and outpatient settings has driven the demand for effective infection control products and protocols.
o Advancements in technology for preventing surgical site infections are revolutionizing the landscape of infection control, offering promising solutions such as advanced antimicrobial coatings, smart monitoring systems, and novel sterilization techniques to enhance patient safety and reduce the incidence of infections in surgical settings.
SEGMENTATION ANALYSIS
Market Segmentation – Procedure, Type of infection, End-User, and Product –
Market by Procedure:
• Laparoscopy
o Laparoscopic procedures, characterized by small incisions and minimally invasive techniques, have become increasingly common across various surgical specialties.
o The market for surgical site infection control in laparoscopy focuses on specialized infection prevention measures tailored to the unique challenges of minimally invasive surgery, including sterilization of laparoscopic instruments, use of antimicrobial coatings on trocars and ports, and maintenance of aseptic techniques during laparoscopic procedures to minimize the risk of infections.
• Orthopedic surgery
• Cardiovascular
• Obstetrics and Gynecology
• Wound Closure
• Plastic & Reconstructive Surgery
• Thoracic Surgery
• Microvascular
• Urology
• Neurosurgery
• Other Procedures
Market by Type of Infection:
• Superficial Incisional SSI
o Superficial incisional surgical site infections (SSIs) are characterized by infections that involve only the skin and subcutaneous tissue at the surgical site.
o While typically less severe compared to deep incisional or organ/space SSIs, they can still lead to complications such as delayed wound healing, prolonged hospital stays, and increased healthcare costs.
o The market for superficial incisional SSI control encompasses a range of preventive measures and products aimed at reducing the risk of infection at the superficial layers of the surgical incision, including antiseptic solutions, antimicrobial dressings, and adhesive barriers.
• Deep Incisional SSI
• Organ or Space SSI
Market by End-User:
• Hospitals
• Ambulatory Surgical Centers
Market by Product:
• Disinfectants
o Skin Disinfectants
o Hand Disinfectants
• Manual Reprocessors Solutions
• Surgical Drapes
• Surgical Gloves
• Skin Preparation Solutions
• Surgical Irrigation
• Surgical Scrubs
• Hair Clippers
• Medical Nonwovens
• Other Products
REGIONAL ANALYSIS
Geographical Study based on Four Major Regions:
• North America: The United States and Canada
o North America, particularly the United States, witnesses a high volume of surgical procedures annually, leading to a greater demand for SSIC solutions.
o The region also boasts some of the most advanced healthcare facilities globally, equipped with modern technologies and resources to implement effective infection control protocols.
o Moreover, North America hosts a vibrant research and development (R&D) ecosystem dedicated to SSIC, leading to innovations in prevention, diagnosis, and treatment. This focus on innovation fosters the development of novel SSIC technologies and products, further propelling the market’s growth.
• Europe: The United Kingdom, Germany, France, Italy, Spain, Poland, Belgium and Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
• Rest of World: Latin America, the Middle East & Africa
COMPETITIVE INSIGHTS
The major players in the global surgical site infection control market are:
• 3M Company
• Becton, Dickinson and Company (BD)
• Getinge AB
• Johnson & Johnson
• Stryker Corporation
Key strategies adopted by some of these companies:
• In March 2022, Invenio unveiled the V90 surgical gown series, introducing a new range of surgical gowns.
• In September 2022, STERIS inaugurated a medical device testing facility in Leipzig, Germany. This state-of-the-art facility expands the company’s capabilities in medical device manufacturing, offering additional packaging and microbiological testing services.
We Offer 10% Free Customization and 3 Months Analyst Support
Frequently Asked Questions (FAQs):
• What are the primary methods for managing surgical site infections?
A: Surgical site infection management involves a combination of strategies such as strict adherence to aseptic techniques, pre-operative antimicrobial prophylaxis, post-operative wound care, and surveillance to detect infections early.

• How are surgical site wound infections categorized?
A: Surgical site wound infections are categorized based on the depth of infection into superficial incisional infections, deep incisional infections, and organ/space infections.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET
2.5.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN GERIATRIC POPULATION
3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
3.2. KEY RESTRAINTS
3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS
3.2.3. RISING USE OF OUTPATIENT TREATMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING RATE OF SURGICAL PROCEDURES
4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTIONS
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.3.2. GROWTH PROSPECT MAPPING FOR GERMANY
4.3.3. GROWTH PROSPECT MAPPING FOR CHINA
4.3.4. GROWTH PROSPECT MAPPING FOR SAUDI ARABIA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY PROCEDURE
5.1. LAPAROSCOPY
5.2. ORTHOPEDIC SURGERY
5.3. CARDIOVASCULAR
5.4. OBSTETRICS AND GYNECOLOGY
5.5. WOUND CLOSURE
5.6. PLASTIC & RECONSTRUCTIVE SURGERY
5.7. THORACIC SURGERY
5.8. MICROVASCULAR
5.9. UROLOGY
5.10. NEUROSURGERY
5.11. OTHER PROCEDURES
6. MARKET BY TYPE OF INFECTION
6.1. SUPERFICIAL INCISIONAL SSI
6.2. DEEP INCISIONAL SSI
6.3. ORGAN OR SPACE SSI
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. AMBULATORY SURGICAL CENTERS
8. MARKET BY PRODUCT
8.1. DISINFECTANTS
8.1.1. SKIN DISINFECTANTS
8.1.2. HAND DISINFECTANTS
8.2. MANUAL REPROCESSORS SOLUTIONS
8.3. SURGICAL DRAPES
8.4. SURGICAL GLOVES
8.5. SKIN PREPARATION SOLUTIONS
8.6. SURGICAL IRRIGATION
8.7. SURGICAL SCRUBS
8.8. HAIR CLIPPERS
8.9. MEDICAL NONWOVENS
8.10. OTHER PRODUCTS
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
9.1.3. NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
9.1.4. KEY PLAYERS IN NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED STATES
9.1.5.1.1. UNITED STATES SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.2. CANADA
9.1.5.2.1. CANADA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2. EUROPE
9.2.1. MARKET SIZE & ESTIMATES
9.2.2. EUROPE SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
9.2.3. EUROPE SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
9.2.4. KEY PLAYERS IN EUROPE SURGICAL SITE INFECTION CONTROL MARKET
9.2.5. COUNTRY ANALYSIS
9.2.5.1. UNITED KINGDOM
9.2.5.1.1. UNITED KINGDOM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.2. GERMANY
9.2.5.2.1. GERMANY SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.3. FRANCE
9.2.5.3.1. FRANCE SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.4. ITALY
9.2.5.4.1. ITALY SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.5. SPAIN
9.2.5.5.1. SPAIN SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.6. POLAND
9.2.5.6.1. POLAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.7. BELGIUM
9.2.5.7.1. BELGIUM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.2.5.8. REST OF EUROPE
9.2.5.8.1. REST OF EUROPE SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3. ASIA-PACIFIC
9.3.1. MARKET SIZE & ESTIMATES
9.3.2. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
9.3.3. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
9.3.4. KEY PLAYERS IN ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET
9.3.5. COUNTRY ANALYSIS
9.3.5.1. CHINA
9.3.5.1.1. CHINA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.2. JAPAN
9.3.5.2.1. JAPAN SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.3. INDIA
9.3.5.3.1. INDIA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.4. SOUTH KOREA
9.3.5.4.1. SOUTH KOREA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.5. INDONESIA
9.3.5.5.1. INDONESIA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.6. THAILAND
9.3.5.6.1. THAILAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.7. VIETNAM
9.3.5.7.1. VIETNAM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.8. AUSTRALIA & NEW ZEALAND
9.3.5.8.1. AUSTRALIA & NEW ZEALAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.3.5.9. REST OF ASIA-PACIFIC
9.3.5.9.1. REST OF ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.4. REST OF WORLD
9.4.1. MARKET SIZE & ESTIMATES
9.4.2. REST OF WORLD SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
9.4.3. REST OF WORLD SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
9.4.4. KEY PLAYERS IN REST OF WORLD SURGICAL SITE INFECTION CONTROL MARKET
9.4.5. REGIONAL ANALYSIS
9.4.5.1. LATIN AMERICA
9.4.5.1.1. LATIN AMERICA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.4.5.2. MIDDLE EAST & AFRICA
9.4.5.2.1. MIDDLE EAST & AFRICA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PARTNERSHIPS & AGREEMENTS
10.1.3. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. 3M COMPANY
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCTS
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. AMERICAN POLYFILM
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCTS
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. ANSELL LTD
10.2.3.1. COMPANY OVERVIEW
10.2.3.2. PRODUCTS
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. BECTON, DICKINSON AND COMPANY (BD)
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCTS
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. BELIMED AG
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCTS
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. BIOMERIEUX SA
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCTS
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. GAMA HEALTHCARE
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. GETINGE AB
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCTS
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. JOHNSON & JOHNSON
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCTS
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. KIMBERLY-CLARK
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCTS
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. SOTERA HEALTH LLC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCTS
10.2.11.3. STRENGTHS & CHALLENGES
10.2.12. STERIS CORPORATION
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCTS
10.2.12.3. STRENGTHS & CHALLENGES
10.2.13. STRYKER CORPORATION
10.2.13.1. COMPANY OVERVIEW
10.2.13.2. PRODUCTS
10.2.13.3. STRENGTHS & CHALLENGES